Clinical Trials Sponsored by Decathlon SE

Total 246 results

Decathlon SE

Recruiting

Assessment of the Safety and Performance of an Elbow Brace in the Prevention of Injuries During Sports Practice

Epicondylitis | Elbow Injury | Tendonitis Elbow

France
Decathlon SE
EFOR, France

Recruiting

Assessment of the Safety and Performance of Elbow Supports in the Context of Epicondylitis or a Return to Sport After Sprain

Epicondylitis | Elbow Sprain

France
Decathlon SE
EFOR, France

Terminated

Assessment of the Safety and Performance of Ankle Ligament Supports in the Context of a Return to Sport After Sprain

Ankle Sprain 1St Degree | Ankle Sprain 2Nd Degree | Ankle Sprain 3Rd Degree

France
Decathlon SE
EFOR, France

Recruiting

Assessment of the Safety and Performance of a Compression Ankle Support in the Prevention of Injuries During Sports Practice

Chronic Pain | Chronic Instability of Ankle Joint

France
Decathlon SE
EFOR, France

Recruiting

Assessment of the Safety and Performance of a Patellofemoral Brace

Patellofemoral Pain Syndrome | Patellar Instability

France
Decathlon SE
EFOR, France

Terminated

Assessment of the Safety and Performance of a Compression Knee Support in the Prevention of Injuries During Sports Practice

Chronic Knee Pain | Chronic Instability of Knee Joint

France
Decathlon SE
EFOR, France

Recruiting

Assessment of the Safety and Performance of a Lumbar Belt

Low Back Pain

France
Decathlon SE
EFOR, France

Recruiting

Assessment of the Safety and Performance of Knee Ligament Supports in the Context of a Return to Sport After Sprain

Anterior Cruciate Ligament Tear | Knee Sprain (Mild) | Knee Sprain (Moderate)

France
Luxembourg Institute of Health
DECATHLON SA

Not yet recruiting

Effect of Shoe Cushioning Position and Properties on Running-related Injury Risk (RRI_Interv5)

Running-related Injury

Luxembourg
Luxembourg Institute of Health
DECATHLON SA

Completed

Effects of Shoe Cushioning and Body Mass on Injury Risk in Running (RRI_Interv4)

Running-Related Injury (First-time)

Luxembourg
BioNTech SE

Recruiting

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Genital Herpes Simplex Type 2

United States
BioNTech SE

Recruiting

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Solid Tumor

United States, United Kingdom, Spain, Singapore
BioNTech SE

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)

Non-Small Cell Lung Cancer

Spain, Germany, Turkey, United States, Hungary, United Kingdom, Poland
BioNTech SE

Recruiting

Dose Escalation Trial of BNT152+153 in Patients With Cancer

Solid Tumor

United States, Czechia
BioNTech SE

Terminated

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT)

Prostate Cancer

United States, Germany, United Kingdom, Hungary
BioNTech SE

Active, not recruiting

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
BioNTech SE

Active, not recruiting

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Solid Tumor | Extensive-stage Small Cell Lung Cancer

United States, Spain, United Kingdom, Germany
Bionorica SE

Completed

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis

Eczema-Prone Skin | Atopic Diathesis

Germany
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

COVID-19 | SARS-CoV-2 Infection

Germany
Bionorica SE

Completed

Sinupret Extract Coated Tablets in Chronic Rhinosinusitis

Chronic Rhinosinusitis

Germany, Poland
Bionorica SE

Completed

Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

Urinary Tract Infection

Germany
Bionorica SE

Completed

Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis

Chronic Sinusitis

Belgium
BioNTech SE

Recruiting

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
BioNTech SE

Recruiting

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Monkeypox

United Kingdom, United States
BioNTech SE

Recruiting

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

Colorectal Cancer Stage II | Colorectal Cancer Stage III

United States, Spain, Germany, Belgium
BioNTech SE

Active, not recruiting

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Solid Tumor

United States, Spain
Bionorica SE

Terminated

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

Mastodynia | Premenstrual Syndrome

Germany
Bionorica SE

Completed

Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Acute Rhinosinusitis

Germany
Bionorica SE

Completed

Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome

Premenstrual Syndrome | Cyclic Mastodynia

Czech Republic
BioNTech SE

Recruiting

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
BioNTech SE

Recruiting

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

Tuberculosis

South Africa
BioNTech SE

Recruiting

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

Tuberculosis

Germany
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults

Covid-19 | Protection Against COVID-19

Germany
BioNTech SE

Completed

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

COVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)

United States, Germany, Turkey, South Africa
BioNTech SE

Terminated

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Gastric Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Canada
BioNTech SE

Completed

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)

Melanoma

Germany
Bionorica SE

Active, not recruiting

Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema (AtoCare-OS)

Atopic Dermatitis | Eczema-Prone Skin

Germany
BioNTech SE

Active, not recruiting

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults

RNA Virus Infections | Virus Diseases | Vaccine Adverse Reaction | Infection Viral | Infections, Respiratory | Protection Against COVID-19 and Infections With SARS CoV 2

Germany
Bionorica SE

Completed

BX-1 in Spasticity Due to Multiple Sclerosis

Spasticity Due to Multiple Sclerosis

Hungary, Czechia, Germany, Poland, Spain
Bionorica SE

Completed

Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)

Urinary Tract Infection

Ukraine
Bionorica SE

Completed

Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

Current Smokers

Belgium
BioNTech SE
Pfizer

Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States
BioNTech SE
Pfizer

Active, not recruiting

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Completed

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

SARS-CoV-2 Infection, COVID-19

United States, Spain, Finland, Poland, Mexico, Brazil
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

COVID-19 | SARS-CoV-2 Infection | Maternal Immunization

United States, United Kingdom, Spain, Brazil, South Africa
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

COVID-19 | SARS-CoV-2 Infection

United States, Brazil, South Africa, Germany, Canada, Israel
BioNTech SE
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

COVID-19 | SARS-CoV-2 Infection

Japan
BioNTech SE
Pfizer

Completed

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Completed

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

COVID-19 | SARS-CoV-2 Infection

United States

3

Subscribe